norfloxacin has been researched along with Infections, Respiratory in 18 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Respiratory tract infections were treated with pefloxacin in fifteen patients, who were hospitalized in the intensive care unit and required artificial ventilation." | 9.06 | Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit. ( Boland, DM; de Jong, D; MacLaren, DM; van Gestel, WC, 1987) |
| "Norfloxacin (NFLX), a new quinolone antibacterial agent, was investigated for its antibacterial activity and clinical efficacy on respiratory tract infections." | 7.67 | [Laboratory and clinical studies of norfloxacin in respiratory tract infections]. ( Fujiue, Y; Ikeda, M; Jyo, T; Kodomari, Y; Kuwabara, M; Muroki, K; Yamakido, M, 1988) |
| "to 20 aged patients with respiratory tract infections." | 5.27 | [Clinical studies of norfloxacin on respiratory tract infections in aged people]. ( Honda, A; Kikuchi, N; Sawada, M; Tabeta, H; Takizawa, H, 1987) |
| " As for adverse effects, nausea and headache were observed in 1 patient and abnormal changes in laboratory findings were noted in 1 patient (slight elevations of GOT and GPT)." | 5.27 | [Clinical evaluation on the usefulness and safety of norfloxacin in a twice-a-day regimen against upper respiratory tract infections]. ( Hasegawa, H; Ito, A; Kurihara, M; Miura, T; Obara, K; Odagiri, S; Okubo, T; Takahashi, H; Yamabe, K, 1987) |
| "Respiratory tract infections were treated with pefloxacin in fifteen patients, who were hospitalized in the intensive care unit and required artificial ventilation." | 5.06 | Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit. ( Boland, DM; de Jong, D; MacLaren, DM; van Gestel, WC, 1987) |
| "We report the case of a female patient who presented fixed exanthema following administration of ciprofloxacin." | 3.69 | Fixed eruption caused by ciprofloxacin without cross-sensitivity to norfloxacin. ( Fernández de Miguel, C; Gómez Martinez, M; Laguna Martinez, JJ; Lozano Ayllón, M; Mosquera, MR; Orta Martiartu, M, 1995) |
| "Norfloxacin (NFLX), a new quinolone antibacterial agent, was investigated for its antibacterial activity and clinical efficacy on respiratory tract infections." | 3.67 | [Laboratory and clinical studies of norfloxacin in respiratory tract infections]. ( Fujiue, Y; Ikeda, M; Jyo, T; Kodomari, Y; Kuwabara, M; Muroki, K; Yamakido, M, 1988) |
| " They were given orally dosage ranging 5." | 1.28 | [Clinical study on norfloxacin in children]. ( Kagami, S; Okada, K, 1990) |
| "Tiamulin was mycoplasmastatic." | 1.28 | In vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens. ( Hannan, PC; O'Hanlon, PJ; Rogers, NH, 1989) |
| "Ciprofloxacin was found to be the most active drug tested against all gram-negative organisms and streptococci, with the exception of Streptococcus faecalis and Streptococcus pneumoniae." | 1.27 | Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy. ( Hoogkamp-Korstanje, JA, 1984) |
| "to 20 aged patients with respiratory tract infections." | 1.27 | [Clinical studies of norfloxacin on respiratory tract infections in aged people]. ( Honda, A; Kikuchi, N; Sawada, M; Tabeta, H; Takizawa, H, 1987) |
| " As for adverse effects, nausea and headache were observed in 1 patient and abnormal changes in laboratory findings were noted in 1 patient (slight elevations of GOT and GPT)." | 1.27 | [Clinical evaluation on the usefulness and safety of norfloxacin in a twice-a-day regimen against upper respiratory tract infections]. ( Hasegawa, H; Ito, A; Kurihara, M; Miura, T; Obara, K; Odagiri, S; Okubo, T; Takahashi, H; Yamabe, K, 1987) |
| "Pefloxacin was given as the single drug (except in one case) to twenty-seven patients with a variety of infections (bone and/or joint: 8; respiratory tract: 6; urinary tract: 5; bacteremia: 4; meninges: 3; other: 1)." | 1.27 | [Pefloxacin: clinical experience]. ( Bertrand, A; Janbon, F; Jonquet, O; Jourdan, J; Santoni, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (61.11) | 18.7374 |
| 1990's | 7 (38.89) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoogkamp-Korstanje, JA | 1 |
| Lozano Ayllón, M | 1 |
| Gómez Martinez, M | 1 |
| Mosquera, MR | 1 |
| Laguna Martinez, JJ | 1 |
| Orta Martiartu, M | 1 |
| Fernández de Miguel, C | 1 |
| Sumano, LH | 1 |
| Ocampo, CL | 1 |
| Brumbaugh, GW | 1 |
| Lizarraga, RE | 1 |
| Zhang, YY | 1 |
| Zhun, BY | 1 |
| Jiang, SC | 1 |
| Aerdts, SJ | 2 |
| van Dalen, R | 2 |
| Clasener, HA | 2 |
| Festen, J | 2 |
| van Lier, HJ | 2 |
| Vollaard, EJ | 2 |
| Ihara, T | 1 |
| Kawaguchi, H | 1 |
| Ito, M | 1 |
| Kamiya, H | 1 |
| Sakurai, M | 1 |
| Okada, K | 1 |
| Kagami, S | 1 |
| Hannan, PC | 1 |
| O'Hanlon, PJ | 1 |
| Rogers, NH | 1 |
| Neu, HC | 1 |
| Newsom, SW | 1 |
| Hayashi, I | 1 |
| Onuma, K | 1 |
| Niwata, Y | 1 |
| Hirai, K | 1 |
| Suzue, S | 1 |
| Irikura, T | 1 |
| Ohno, I | 1 |
| Ida, S | 1 |
| Boland, DM | 1 |
| van Gestel, WC | 1 |
| MacLaren, DM | 1 |
| de Jong, D | 1 |
| Kuwabara, M | 1 |
| Muroki, K | 1 |
| Fujiue, Y | 1 |
| Ikeda, M | 1 |
| Kodomari, Y | 1 |
| Jyo, T | 1 |
| Yamakido, M | 1 |
| Tabeta, H | 1 |
| Sawada, M | 1 |
| Honda, A | 1 |
| Takizawa, H | 1 |
| Kikuchi, N | 1 |
| Okubo, T | 1 |
| Ito, A | 1 |
| Takahashi, H | 1 |
| Miura, T | 1 |
| Odagiri, S | 1 |
| Hasegawa, H | 1 |
| Kurihara, M | 1 |
| Yamabe, K | 1 |
| Obara, K | 1 |
| Bertrand, A | 1 |
| Janbon, F | 1 |
| Jourdan, J | 1 |
| Jonquet, O | 1 |
| Santoni, A | 1 |
1 review available for norfloxacin and Infections, Respiratory
| Article | Year |
|---|---|
[Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. b. Synthetic antibacterial agents].
Topics: 4-Quinolones; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Drug Resistance | 1987 |
5 trials available for norfloxacin and Infections, Respiratory
| Article | Year |
|---|---|
Effectiveness of two fluoroquinolones for the treatment of chronic respiratory disease outbreak in broilers.
Topics: Animals; Anti-Infective Agents; Body Weight; Chickens; Chronic Disease; Disease Outbreaks; Enrofloxa | 1998 |
[Clinical evaluation of enoxacin].
Topics: Adult; Dysentery, Bacillary; Enoxacin; Female; Gram-Negative Bacterial Infections; Humans; Male; Mid | 1991 |
Antibiotic prophylaxis of respiratory tract infection in mechanically ventilated patients. A prospective, blinded, randomized trial of the effect of a novel regimen.
Topics: Administration, Topical; Amphotericin B; Bacteria; Cefotaxime; Colistin; Double-Blind Method; Drug T | 1991 |
Prevention of bacterial colonization of the respiratory tract and stomach of mechanically ventilated patients by a novel regimen of selective decontamination in combination with initial systemic cefotaxime.
Topics: Adult; Aged; Bacteria; Cefotaxime; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Hu | 1990 |
Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit.
Topics: Bacterial Infections; Clinical Trials as Topic; Critical Care; Drug Resistance, Microbial; Humans; N | 1987 |
12 other studies available for norfloxacin and Infections, Respiratory
| Article | Year |
|---|---|
Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Dose-Response Relationship, Dr | 1984 |
Fixed eruption caused by ciprofloxacin without cross-sensitivity to norfloxacin.
Topics: Ciprofloxacin; Cross Reactions; Drug Eruptions; Exanthema; Female; Humans; Middle Aged; Norfloxacin; | 1995 |
[Clinical evaluation of norfloxacin in children].
Topics: Adolescent; Age Factors; Bacteria; Child; Child, Preschool; Drug Evaluation; Drug Resistance, Microb | 1990 |
[Clinical study on norfloxacin in children].
Topics: Administration, Oral; Adolescent; Age Factors; Child; Child, Preschool; Drug Evaluation; Female; Hum | 1990 |
In vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bordetella; Diterpenes; Gentamicins; Haemophi | 1989 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
The clinical use of quinolones.
Topics: Ciprofloxacin; Escherichia coli; Feces; Female; Genital Diseases, Female; Genital Diseases, Male; Hu | 1986 |
[Combination effects of norfloxacin and fosfomycin against respiratory infections].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Fosfomycin; Humans; Male; Middle Aged; Norfloxacin; | 1987 |
[Laboratory and clinical studies of norfloxacin in respiratory tract infections].
Topics: Adult; Aged; Bacteria; Bacterial Infections; Female; Humans; Male; Microbial Sensitivity Tests; Midd | 1988 |
[Clinical studies of norfloxacin on respiratory tract infections in aged people].
Topics: Aged; Aged, 80 and over; Bacteria; Drug Evaluation; Female; Humans; Male; Norfloxacin; Respiratory T | 1987 |
[Clinical evaluation on the usefulness and safety of norfloxacin in a twice-a-day regimen against upper respiratory tract infections].
Topics: Adolescent; Adult; Aged; Bacteria; Drug Administration Schedule; Drug Evaluation; Female; Humans; Ma | 1987 |
[Pefloxacin: clinical experience].
Topics: Acinetobacter Infections; Adult; Aged; Bacterial Infections; Enterobacteriaceae Infections; Enteroco | 1985 |